Realm Therapeutics - Notice of Results

April 26, 2018
RNS Number : 2760M
Realm Therapeutics PLC
26 April 2018
 

Realm Therapeutics plc

("Realm Therapeutics", "Realm", or the "Company")

 

Notice of Full Year 2017 Results

 

 

April 26, 2018 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company expects to release its results for the year ended December 31, 2017 on May 2, 2018.

 

A conference call and live audio webcast is planned for 9 am ET / 6 am PT / 2 pm BST on May 2, 2018. To participate in the conference call, please use the below dial in details or to access the audio webcast, please see the Investor Relations section of Realms's website, www.realmtx.com.

 

Conference call number(s):

 

US Toll-Free: +1 855-857-0686

US Toll: +1 631-913-1422

 

UK Toll-Free: 08003589473

UK Toll: +44 3333000804

 

Conference call pin code: 26292059#

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of atopic dermatitis, and the Company is exploring its efficacy in other dermatology indications which include acne vulgaris and psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

 

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

Contact:

 

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212-600-1902

 

Argot Partners

Stephanie Marks/Susan Kim

+1 212-600-1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORXQLFLVZFXBBB

Search Investor Relations